# Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor

> **NCT03512119** · — · COMPLETED · sponsor: **University Hospital, Strasbourg, France** · enrollment: 55 (actual)

## Conditions studied

- Cystic Fibrosis Homozygous for Phe 508 Del CFTR
- Glucose Intolerance or Newly Diagnosis Diabetes

## Interventions

- **DRUG:** Lumacaftor-Ivacaftor treatment

## Key facts

- **NCT ID:** NCT03512119
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-11
- **Primary completion:** 2019-04-10
- **Final completion:** 2019-04-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03512119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03512119, "Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03512119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*